Friday, July 10, 2026
🇺🇸 FDA

pharma · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · metastatic or unresectable, recurrent HNSCC

Createrna Science and

Wuhan Createrna Science and Technology Co., Ltd

Createrna Science and drug portfolio — 87 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
shanghai, CN, London HQ
26 Employees
NMPA registrant Type
Company details
Status
Public
HQ
shanghai, CN, London
Employees
26
Programs
51
Drugs
87
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

Createrna Science and pipeline

Portfolio lens on 87 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Createrna Science and drug portfolio — 87 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

87 compounds

  1. acalabrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  2. administered

    Development asset linked to Createrna Science and in public FDA and regional records.

  3. alpelisib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform.

    Target
    Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
    Mechanism
    PI3-kinase p110-alpha subunit inhibitor

  4. alzheimer

    Development asset linked to Createrna Science and in public FDA and regional records.

  5. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  6. belantamab mafodotin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Createrna Science and's portfolio. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tumor necrosis factor receptor superfamily member 17 binding agent

  7. bendamustine

    Development asset linked to Createrna Science and in public FDA and regional records.

  9. betamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  10. bortezomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  11. botulinum toxin type a

    Musculo-skeletal system (M03)

    Musculo-skeletal system (M03) compound in Createrna Science and's portfolio. Molecular target: Synaptosomal-associated protein 25.

    Target
    Synaptosomal-associated protein 25
    Mechanism
    Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme

  12. calcium chloride

    US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.

    Mechanism
    Dihydrofolate reductase inhibitor

  13. canagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  14. capsule

    Development asset linked to Createrna Science and in public FDA and regional records.

  15. capsules

    Development asset linked to Createrna Science and in public FDA and regional records.

  16. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  17. chemotherapy

    Development asset linked to Createrna Science and in public FDA and regional records.

  18. chloride

    Development asset linked to Createrna Science and in public FDA and regional records.

  19. control

    Development asset linked to Createrna Science and in public FDA and regional records.

  20. corticosteroid

    Development asset linked to Createrna Science and in public FDA and regional records.

  21. cyclophosphamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  22. cytarabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  23. dapagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  24. daratumumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  25. decitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.

    Target
    DNA (cytosine-5)-methyltransferase 1
    Mechanism
    DNA (cytosine-5)-methyltransferase 1 inhibitor

  26. denosumab

    Musculo-skeletal system (M05)

    US regulatory status: approved. Molecular target: Tumor necrosis factor ligand superfamily member 11.

    Target
    Tumor necrosis factor ligand superfamily member 11
    Mechanism
    Tumor necrosis factor ligand superfamily member 11 inhibitor

  27. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  28. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Createrna Science and's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  29. doxorubicin hydrochloride

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA topoisomerase II alpha inhibitor

  30. durvalumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  31. edoxaban

    Blood and blood forming organs (B01)

    US regulatory status: approved. Mechanism: Coagulation factor X inhibitor.

    Mechanism
    Coagulation factor X inhibitor

  32. empagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  33. epithelial

    Development asset linked to Createrna Science and in public FDA and regional records.

  34. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  35. etoposide

    US regulatory status: approved. Molecular target: DNA topoisomerase II.

    Target
    DNA topoisomerase II
    Mechanism
    DNA topoisomerase II inhibitor

  36. fluorouracil

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  37. folic

    Development asset linked to Createrna Science and in public FDA and regional records.

  38. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  39. gemcitabine hydrochloride

    US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).

    Target
    DNA polymerase (alpha/delta/epsilon)
    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  40. gilteritinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Createrna Science and's portfolio. Molecular target: Receptor-type tyrosine-protein kinase FLT3.

    Target
    Receptor-type tyrosine-protein kinase FLT3
    Mechanism
    Tyrosine-protein kinase receptor FLT3 inhibitor

  41. hexocyclium methylsulfate

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M1 antagonist

  42. ibrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  43. idelalisib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform.

    Target
    Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
    Mechanism
    PI3-kinase p110-delta subunit inhibitor

  44. ifosfamide

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  45. infusion

    Development asset linked to Createrna Science and in public FDA and regional records.

  46. inhibitor

    Development asset linked to Createrna Science and in public FDA and regional records.

  47. injection

    Development asset linked to Createrna Science and in public FDA and regional records.

  48. irinotecan

    Development asset linked to Createrna Science and in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.

    Mechanism
    DNA topoisomerase I inhibitor

  49. irinotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I inhibitor

  50. isatuximab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Createrna Science and's portfolio. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  51. lenalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  52. lutetium (177lu) chloride

    Various (V10)

    Various (V10) compound in Createrna Science and's portfolio. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  53. mecasermin

    Systemic hormonal preparations (H01)

    Systemic hormonal preparations (H01) compound in Createrna Science and's portfolio. Molecular target: Insulin-like growth factor 1 receptor.

    Target
    Insulin-like growth factor 1 receptor
    Mechanism
    Insulin-like growth factor I receptor agonist

  54. mecasermin rinfabate

    Development asset linked to Createrna Science and in public FDA and regional records. Molecular target: Insulin-like growth factor 1 receptor.

    Target
    Insulin-like growth factor 1 receptor
    Mechanism
    Insulin-like growth factor I receptor agonist

  55. methotrexate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Dihydrofolate reductase inhibitor

  56. midostaurin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Platelet-derived growth factor receptor.

    Target
    Platelet-derived growth factor receptor
    Mechanism
    Protein kinase C (PKC) inhibitor

  57. monohydrate

    Development asset linked to Createrna Science and in public FDA and regional records.

  58. nacl

    Development asset linked to Createrna Science and in public FDA and regional records.

  59. normal

    Development asset linked to Createrna Science and in public FDA and regional records.

  60. ointment

    Development asset linked to Createrna Science and in public FDA and regional records.

  61. olaparib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: PARP 1, 2 and 3.

    Target
    PARP 1, 2 and 3
    Mechanism
    PARP 1, 2 and 3 inhibitor

  62. onabotulinumtoxina

    US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.

    Target
    Synaptosomal-associated protein 25
    Mechanism
    Synaptosomal-associated protein 25 inhibitor

  63. paclitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  64. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  65. peritoneal

    Development asset linked to Createrna Science and in public FDA and regional records.

  66. pirtobrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  67. placebo

    Development asset linked to Createrna Science and in public FDA and regional records.

  68. pomalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  69. powder

    Development asset linked to Createrna Science and in public FDA and regional records.

  70. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  71. prolia

    Development asset linked to Createrna Science and in public FDA and regional records. Molecular target: Tumor necrosis factor ligand superfamily member 11.

    Target
    Tumor necrosis factor ligand superfamily member 11
    Mechanism
    Tumor necrosis factor ligand superfamily member 11 inhibitor

  72. protocol

    Development asset linked to Createrna Science and in public FDA and regional records.

  73. ramucirumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor 2.

    Target
    Vascular endothelial growth factor receptor 2
    Mechanism
    Vascular endothelial growth factor receptor 2 inhibitor

  74. rituximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.

    Target
    B-lymphocyte antigen CD20
    Mechanism
    B-lymphocyte antigen CD20 binding agent

  75. saline

    Development asset linked to Createrna Science and in public FDA and regional records.

  76. selpercatinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET.

    Target
    Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET
    Mechanism
    Tyrosine-protein kinase receptor RET inhibitor

  78. solution

    Development asset linked to Createrna Science and in public FDA and regional records.

  79. stro-

    Development asset linked to Createrna Science and in public FDA and regional records.

  80. tablet

    Development asset linked to Createrna Science and in public FDA and regional records.

  81. tablets

    Development asset linked to Createrna Science and in public FDA and regional records.

  82. therapy

    Development asset linked to Createrna Science and in public FDA and regional records.

  83. topotecan hydrochloride

    US regulatory status: approved. Molecular target: DNA topoisomerase 1.

    Target
    DNA topoisomerase 1
    Mechanism
    DNA topoisomerase I, mitochondrial inhibitor

  84. trastuzumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.

    Target
    Receptor tyrosine-protein kinase erbB-2
    Mechanism
    Receptor protein-tyrosine kinase erbB-2 inhibitor

  85. venetoclax

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.

    Target
    Apoptosis regulator Bcl-2
    Mechanism
    Apoptosis regulator Bcl-2 inhibitor

  86. vincristine

    Development asset linked to Createrna Science and in public FDA and regional records. Mechanism: Tubulin inhibitor.

    Mechanism
    Tubulin inhibitor

  87. zanubrutinib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.